Related Experiment Videos
Aripiprazole in schizophrenia: consensus guidelines
M J Travis1, T Burns, S Dursun
1Institute of Psychiatry, London, UK.
International Journal of Clinical Practice
|April 28, 2005
Summary
Aripiprazole offers a new atypical antipsychotic option for schizophrenia treatment. These UK guidelines detail best practices for its prescribing and use, addressing limitations of older medications.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Schizophrenia necessitates long-term antipsychotic treatment.
- Conventional antipsychotics cause side effects like extrapyramidal symptoms.
- Atypical antipsychotics offer an alternative but have their own side effects, including weight gain, sedation, and hyperprolactinemia.
Framework:
- Aripiprazole is a novel atypical antipsychotic agent.
- It presents a new option for managing schizophrenia.
- Guidelines are based on consensus from the Schizophrenia Innovation Working Group.
Implementation:
- Focuses on best practices for prescribing aripiprazole.
- Outlines appropriate use within the UK context.
- Addresses the need for alternative treatment options due to limitations of existing medications.
Implications:
- Provides clinicians with guidance on a new therapeutic option.
- Aims to optimize the management of schizophrenia with aripiprazole.
- Contributes to informed prescribing decisions for antipsychotic medications.